Company intelligence / Profile preview
EverZom
Paris, Ile-de-France, Franceeverzom.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
EVerZom’s lead candidate, EVerGel—a combination of exosomes with a hydrogel biomaterial—has shown highly promising preclinical results in a porcine model of complex perianal fistulas associated with Crohn’s disease. Complete healing was achieved in 87.5% of treated cases versus only 12.5% in controls after four weeks. Clinical trials are targeted to begin as early as 2026; commercialization could occur by around 2030 if successful.
- Therapeutic areas
- GastroenterologyNeurologyOther
- Modalities
- Exosome-based therapyHydrogel-based drug delivery therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Around twenty global partnerships across human health, animal health, and cosmetics sectors; specific partners not named publicly as of June 2025
Beyond the preview
Go deeper on EverZom.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EverZom.